CIK 0001095981 · Non-accelerated filer<br>Smaller reporting company
CERENOME, INC.
Sign in to watch- Ticker
- CNSY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330827593
- Phone
- 737.255.7194
- Business address
- 6420 LEVIT GREEN BOULEVARD, SUITE 310, HOUSTON, TX, 77021
- Former names
- PLUS THERAPEUTICS, INC., CYTORI THERAPEUTICS, INC., MACROPORE INC
- 4 Derivatives Options or other derivatives
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- FWP Offering Free Writing Prospectus
- 8-K Event Material agreement
- S-3MEF Other S-3MEF
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Executive or director change
- 4 Open-market buy Chief Executive Officer bought 6,000 shares at an average $5.06 ($30,375)
- 4 Open-market buy Chief Executive Officer bought 6,000 shares at $4.87 ($29,220)
- 4 Open-market buy Chief Executive Officer bought 4,000 shares at an average $4.77 ($19,099)
- 4 Open-market buy Chief Executive Officer bought 4,000 shares at an average $4.65 ($18,591)
- 4 Open-market buy Director bought 5,000 shares at $4.73 ($23,650)
- 4 Open-market buy President bought 10,000 shares at an average $4.29 ($42,862)
- 4 Open-market buy President bought 5,500 shares at an average $4.36 ($23,995)
- 4 Open-market buy Senior Vice President Asia Pac bought 2,000 shares at $4.20 ($8,400)
- 4 Open-market buy President bought 2,213 shares at an average $4.12 ($9,120)
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 10-Q Report Quarterly Report
Page 62 of 74 · 1,465 filings